About this resource:
Source: U.S. Preventive Services Task Force
Last Reviewed: September 2019
The U.S. Preventive Services Task Force (USPSTF) recommends that health care providers offer to prescribe risk-lowering medicines — like tamoxifen, raloxifene, or aromatase inhibitors — to women age 35 years and older who are at increased risk of breast cancer and low risk of side effects from the medicine. USPSTF recommends against use of these medicines in women age 35 years and older who aren't at increased risk for breast cancer.
Objectives related to this resource (2)
U.S. Preventive Services Task Force. (2019). Breast Cancer: Medication Use to Reduce Risk. Retrieved from https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-medications-for-risk-reduction